Swedish Orphan Biovitrum AB - Company Profile

Powered by

All the data and insights you need on Swedish Orphan Biovitrum AB in one report.

  • Save hours of research time and resources with
    our up-to-date Swedish Orphan Biovitrum AB Strategy Report

  • Understand Swedish Orphan Biovitrum AB position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Swedish Orphan Biovitrum AB: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS). Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has an operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.

Gain a 360-degree view of Swedish Orphan Biovitrum AB and make more informed decisions for your business Gain a 360-degree view of Swedish Orphan Biovitrum AB and make more informed decisions for your business Find out more
Headquarters Sweden

Address Tomtebodavagen 23a, Solna, 17165


Telephone 46 8 6972000

No of Employees 1,831

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange SOBI (STO)

Revenue (2022) $2.1B 17.7% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ -8.7% (2022 vs 2021)

Market Cap* $9.2B

Net Profit Margin (2022) XYZ -22.5% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Swedish Orphan Biovitrum AB premium industry data and analytics

150+

Clinical Trials

Determine Swedish Orphan Biovitrum AB go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

90+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Swedish Orphan Biovitrum AB’s relevant decision makers and contact details.

80+

Catalyst Calendar

Proactively evaluate Swedish Orphan Biovitrum AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Swedish Orphan Biovitrum AB’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Swedish Orphan Biovitrum AB and assess market opportunity for new entrants with patient population 8-year forecasts.

18+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

17+

Marketed Drugs

Understand Swedish Orphan Biovitrum AB’s commercialized product portfolio to stay one step ahead of the market.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Investigators

Review investigator profiles and find information on trial contacts across Swedish Orphan Biovitrum AB, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Swedish Orphan Biovitrum AB’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
-
Hematology:
Elocta
XYZ
XYZ
XYZ
Understand Swedish Orphan Biovitrum AB portfolio and identify potential areas for collaboration Understand Swedish Orphan Biovitrum AB portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Regulatory Approval In May, the company received approval from the European Commission (EC) for Aspaveli (pegcetacoplan) or treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
2024 Regulatory Approval In May, Sobi North America secured the US Food and Drug Administration grant Fast Track designation to emapalumab-lzsg being investigated as a potential therapeutic option in patients with Macrophage Activation Syndrome (MAS).
2024 Contracts/Agreements In May, the company and UT Health San Antonio entered an agreement with BerGenBio ASA to study bemcentinib combined with pacritinib in patients with advanced lung adenocarcinoma, funded by a grant from the National Cancer Institute.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Swedish Orphan Biovitrum AB BioGaia AB Hansa Biopharma AB Vivesto AB AMAG Pharmaceuticals Inc
Headquarters Sweden Sweden Sweden Sweden United States of America
City Solna Stockholm Lund Solna Waltham
State/Province - - - - Massachusetts
No. of Employees 1,831 211 166 6 440
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Annette Clancy Chairman Executive Board 2014 70
Guido Oelkers Chief Executive Officer Senior Management 2017 59
Henrik Stenqvist Chief Financial Officer Senior Management 2018 57
Lydia Abad-Franch Chief Medical Officer; Head - Research, Development Senior Management 2023 53
Torbjorn Hallberg General Counsel; Head - Legal Affairs Senior Management 2018 55
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Swedish Orphan Biovitrum AB key executives to enhance your sales strategy Gain insight into Swedish Orphan Biovitrum AB key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer